(Adnkronos) - Iezzi (AbbVie), Portfolio ricco per soluzioni, ma prevenzione resta pilastro fondamentale. Galdolfi (UniParma), grazie a nuove tecniche e a farmaci a lento rilascio chirurgia recupera posizioni e viene proposta in fasi medio iniziali del glaucoma
Category
🗞
NewsTranscript
00:00GLAUCOMA
00:06Maculopathy and Glaucoma Retinopathy
00:09against the thunders of the eye and silent companions for over 3 million Italians
00:14the global biopharmaceutical company AbbVie took to the field
00:18as well as to cure the dry eye, a chronic alteration of the tear film
00:22that affects about 20-30% of the population after 50 years of age
00:27and there are 63,000 people who risk their eyesight every year
00:30because affected by a maculopathy
00:331 million those who currently live with the macular degeneration related to age
00:381.2 million patients estimated with glaucoma
00:41equal to 2% of the population over 40
00:44and over 1 million people who suffer from diabetic retinopathy
00:48main complication of the disease of sweet blood
00:51and first cause of blindness in working age
00:55in all three therapeutic indications AbbVie has a rich pipeline
00:59for the dry eye there are innovative molecules
01:02that combine the current effectiveness required by doctors
01:06better well-being by the patient
01:08therefore better comfort in delivery and less side effects
01:12for the glaucoma
01:14although having solutions that can accompany the patient during the day
01:19the further evolution is to have the traditional molecule
01:23of which the effectiveness is recognized and confirmed
01:26but in the form of a device that allows one supply or two per year
01:31to maintain the effectiveness
01:33regardless of the patient's adherence, thus facilitating it
01:36the treatment of glaucoma that aims to reduce intraocular pressure
01:41and the consequent damage to the optic nerve
01:43has been re-evaluated and revolutionized in recent times
01:47and as it has been underlined at the Third Congress of ASISO
01:50the Italian Society of Ophthalmological Sciences
01:53the laser that came after the therapy with daily colliris
01:56is launched at the first place of the cures
01:58together with new formulations of slow-release eye drugs
02:02Usually the surgery is put in the background
02:05it is the sentence that comes to the patient when everything has failed
02:09with these techniques the surgery is recovered
02:12and is offered and proposed in the mid-initial phases of the disease
02:182. The drops
02:20There is a lot of work on what?
02:23On the development of different ways to get a drug into an eye
02:28that is, no longer using the colliris as a vehicle
02:32but, for example, supplying slow-release systems
02:38that through a supply last a month or months
02:44or through a micro-injection inside the eye itself
02:49allow for several months to go on with a controlled pressure
02:54But not only
02:56The real novelty is that in the field of retinal disease
03:00so both in senile and humid maculopathy
03:02and in that in diabetic retinopathy
03:05of which we know a strong incidence and prevalence
03:08ABVI is bringing the innovation of gene therapy
03:12Right now in Italy 10 centers are experimenting with gene therapy for this
03:18Fundamental then for ABVI is also prevention
03:22Although, for example, there are about 4 million people in Italy with diabetes
03:27just 18% is subject, according to the data of the Ministry of Health
03:31to the eye exam
03:33Yet
03:34The invitation is recurring and that of the entire diabetic population
03:38to do periodic eye examinations
03:41and ABVI supports the eye exam in partnership with scientific societies
03:45and patient associations
03:47to be sure to be able to intervene at the right time with the right drug